Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 96Pancreatic Neoplasms 83Carcinoma, Non-Small-Cell Lung 79Ovarian Neoplasms 52Fallopian Tube Neoplasms 47Triple Negative Breast Neoplasms 42Lung Neoplasms 32Neoplasm Metastasis 27Squamous Cell Carcinoma of Head and Neck 23Neoplasms 19Breast Neoplasms, Male 18Endometrial Neoplasms 17Uterine Cervical Neoplasms 16Melanoma 16Brenner Tumor 16Stomach Neoplasms 15Carcinoma, Ovarian Epithelial 15Esophageal Neoplasms 13Adenocarcinoma of Lung 13Inflammatory Breast Neoplasms 11Cholangiocarcinoma 10Adenocarcinoma, Bronchiolo-Alveolar 9Urinary Bladder Neoplasms 8Unspecified Adult Solid Tumor, Protocol Specific 8Oropharyngeal Neoplasms 8Carcinoma, Transitional Cell 8Adenocarcinoma Of Esophagus 8Mouth Neoplasms 7Esophageal Squamous Cell Carcinoma 7Colorectal Neoplasms 7

Interventions

Paclitaxel 3Bevacizumab 3fludarabine 2Nivolumab 2Gemcitabine 2Carboplatin 2rucaparib 1pembrolizumab 1liposomal doxorubicin 1dostarlimab 1Taxes 1Sunitinib 1Stem Cell Transplantation 1Sirolimus 1Radiotherapy 1Melphalan 1Ipilimumab 1Immunoglobulin G 1Erlotinib Hydrochloride 1Doxorubicin 1Docetaxel 1Disulfides 1Dexamethasone 1Celecoxib 1Capecitabine 1Busulfan 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Adenocarcinoma, Clear Cell × Taxes × Clear all
NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,052 enrolled 27 charts
Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡